---
title: "Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278958185.md"
description: "Chardan Capital analyst Keay Nakae has maintained a Buy rating on ProQR (PRQR) with a price target of $4.00. Nakae, a 4-star analyst with a 39.80% success rate, focuses on the Healthcare sector. The current analyst consensus on ProQR is a Strong Buy, with an average price target of $6.50."
datetime: "2026-03-12T23:55:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278958185.md)
  - [en](https://longbridge.com/en/news/278958185.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278958185.md)
---

# Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)

Chardan Capital analyst Keay Nakae maintained a Buy rating on ProQR today and set a price target of $4.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Nakae is a 4-star analyst with an average return of 3.8% and a 39.80% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and ProQR.

Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $6.50.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PRQR.US](https://longbridge.com/en/quote/PRQR.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday](https://longbridge.com/en/news/282051007.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs](https://longbridge.com/en/news/282092937.md)